AstraZeneca's Tagrisso Shows Promise in Slowing Lung Cancer Progression
TL;DR Summary
AstraZeneca's drug Tagrisso significantly reduces the progression of stage 3 lung cancer by 84% in patients with a specific genetic mutation, potentially changing treatment practices according to experts at the American Society of Clinical Oncology.
- ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers STAT
- AstraZeneca's Lung, Breast Cancer Drugs Markedly Slow Disease Bloomberg
- Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable EGFR-Mutated NSCLC OncLive
- At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer MedCity News
- LAURA Shows Osimertinib Effective in Treating EGFR+ NSCLC After Chemo/Radiation Targeted Oncology
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
85%
228 → 35 words
Want the full story? Read the original article
Read on STAT